10X GENOMICS INC

10X Genomics Q2 2026 results: modest revenue rise, improved gross margin, and a new higher revenue outlook amid growing customer demand and key research partnerships.

10X Genomics Q2 2026: $151M revenue, better-than‑expected EPS, new Proteintech Genomics acquisition, and multi‑omics growth forecast.

10X Genomics: Morgan Stanley’s equal‑weight downgrade reveals neutral outlook, limited upside, and caution amid negative P/E and market volatility.

10X Genomics Inc. is at a crossroads, with Wall Street analysts offering conflicting views on its future, as some predict a potential 55.85% rally while others warn of deeper systemic issues.